Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 From SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 From SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
TYRA is hosting a conference call and webcast on CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain.
加州卡爾斯巴德，2024年10月23日 /美通社/ - Tyra Biosciences, Inc.（納斯達克: TYRA）, 一家處於臨床階段的生物技術公司，專注於開發針對大規模機會的FGFR生物學的下一代精準藥物，今天宣佈將於2024年10月25日上午8:00（東部時間）舉行電話會議和網絡直播，分享TYRA-300在轉移性尿路上皮癌（mUC）SURF301第1/2期研究的中期臨床結果。這些數據將在2024年10月23日至25日於西班牙巴塞羅那舉行的第36屆EORTC-NCI-AACR（ENA）分子靶向和癌症治療研討會上以晚報口頭報告的形式呈現。
Gary Steinberg, MD, Professor of Urology, Department of Urology, Rush University Medical Center, will be joining members of TYRA's management team on the call and will be available during Q&A.
加入TYRA管理團隊成員的Gary Steinberg, MD，泌尿外科教授，拉什大學醫療中心泌尿科，將參加電話會議，並在問答環節中提供幫助。
Conference Call Information
電話會議信息
TYRA is hosting a conference call and webcast on October 25, 2024, at 8am ET to review the interim clinical data demonstrated with TYRA-300 in mUC. Participants may access a live webcast of the call and the associated slide presentation on the "For Investors" page of the TYRA website at . To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.
TYRA將於2024年10月25日上午8時（東部時間）舉行電話會議和網絡直播，審查與mUC中TYRA-300展示的中期臨床數據。參與者可以在TYRA網站的"投資者"頁面上查看直播網絡電話會議和相關幻燈片演示。要通過電話參與，請提前在此註冊。成功註冊後，所有電話參與者將收到確認電子郵件，詳細說明如何加入電話會議，包括撥入號碼以及可用於訪問會議的獨特密碼和註冊ID。電話會議和網絡直播的重播將在公司網站上歸檔至少90天。 link。
About Tyra Biosciences
關於Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.
泰拉生物科技公司（TYRA）(納斯達克：TYRA）是一家致力於開發針對FGFR生物學上大機遇的下一代精準藥物的臨床階段生物技術公司。 公司的內部精準醫學平台SNÅP，通過 SNÅP快照的迭代分子，幫助預測通過獲得性耐藥到現有治療方案的最有可能引起基因變化。 TYRA 的初始重點是將其加速的小分子藥物發現引擎應用於發展定向腫瘤學和基因定義條件的治療方案。TYRA總部位於加州卡爾斯巴德。
For more information about our science, pipeline and people, please visit and engage with us on LinkedIn.
有關我們的科學、產品管道和團隊的更多信息，請訪問 並且與我們互動 LinkedIn.
Contact:
聯繫方式：
Amy Conrad
[email protected]
Amy Conrad
[email protected]
SOURCE Tyra Biosciences
資料來源：Tyra Biosciences
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
想要您公司的新聞在PRNEWSWIRE.COM上特色呈現嗎？
譯文內容由第三人軟體翻譯。
